证券日报网讯盈康生命（300143）10月10日在互动平台回答投资者提问时表示，截至2025年9月30日， 公司股东总数为19，839户。 ...

Core Viewpoint - Yingkang Life's stock price increased by 1.78% on September 30, with a trading volume of 124 million yuan, indicating positive market sentiment towards the company [1]. Financing Summary - On September 30, Yingkang Life had a financing buy-in amount of 13.63 million yuan and a financing repayment of 27.28 million yuan, resulting in a net financing outflow of 13.65 million yuan [1]. - As of September 30, the total financing and securities lending balance for Yingkang Life was 269 million yuan, which accounts for 3.67% of its market capitalization, indicating a high level of financing activity compared to the past year [1]. - The company had a securities lending repayment of 16,800 shares and a securities lending sell-out of 200 shares, with a sell-out amount of 2,284 yuan, reflecting low securities lending activity [1]. Company Overview - Yingkang Life Technology Co., Ltd. is located in Qingdao, Shandong Province, and was established on August 6, 1998, with its listing date on December 9, 2010 [2]. - The company's main business involves medical devices and medical services, with a focus on developing, producing, and selling advanced radiation therapy equipment and establishing a specialized cancer treatment service network [2]. - The revenue composition of Yingkang Life includes 77.47% from medical services and 22.53% from medical devices and consumables [2]. Financial Performance - For the first half of 2025, Yingkang Life reported a revenue of 843 million yuan, representing a year-on-year growth of 2.40%, and a net profit attributable to shareholders of 61.83 million yuan, which is a 12.82% increase compared to the previous year [2]. Dividend Information - Since its A-share listing, Yingkang Life has distributed a total of 29.48 million yuan in dividends, with no dividends paid in the last three years [3].

Group 1 - The core viewpoint of the news is that Yingkang Life has shown a positive stock performance with a year-to-date increase of 24.46% and a recent price of 11.45 CNY per share, despite some fluctuations in trading volume and net capital outflow [1] - As of September 19, the number of shareholders for Yingkang Life decreased by 16.28% to 20,500, while the average circulating shares per person increased by 19.45% to 31,286 shares [2] - The company reported a revenue of 843 million CNY for the first half of 2025, reflecting a year-on-year growth of 2.40%, and a net profit attributable to shareholders of 61.83 million CNY, which is a 12.82% increase year-on-year [2] Group 2 - Yingkang Life specializes in medical devices and services, focusing on cancer prevention, diagnosis, treatment, and rehabilitation, with a revenue composition of 77.47% from medical services and 22.53% from medical devices and consumables [2] - The company has cumulatively distributed 29.48 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]

Core Viewpoint - The company, Yingkang Life, emphasizes its commitment to clinical value and long-term strategy in the fields of brain-computer interfaces and rehabilitation robotics, focusing on technological maturity and business synergy in its clinical explorations and collaborations [1] Group 1: Strategic Focus - The company is strategically focused on the entire industry chain of tumor pre-diagnosis and treatment, consistently communicating this strategy through regular reports, announcements, and investor engagement activities [1] - The management plans to leverage resources from the Haier ecosystem to steadily enhance core capabilities and actively seek frontier collaboration opportunities that align with its strategy [1] Group 2: Operational Approach - The company prioritizes the maturity of technology and commercial viability in its innovation efforts, reflecting the high technical barriers and stringent regulatory requirements of the medical industry [1] - The management will continue to optimize team structure and attract professional talent to drive high-quality development [1] Group 3: Market Outlook - The company expresses strong confidence in the long-term prospects of the health industry and aims to reward investors' trust through solid operational performance [1]

Core Viewpoint - The company emphasizes the importance of fair and compliant information disclosure, ensuring that all significant information is disclosed in accordance with regulations [1] Group 1: Company Operations - The company reports that its operations are normal and that various strategies are being steadily advanced [1] - There are no significant undisclosed matters that should have been disclosed [1] Group 2: Information Disclosure - The company is committed to optimizing the content and format of its disclosures to ensure timeliness and transparency [1] - The company will actively use diverse channels to communicate its value to the market [1] Group 3: Business Focus - The company remains focused on its core business and is dedicated to achieving high-quality development [1]

Core Viewpoint - The company emphasizes its commitment to clinical value and long-term strategy in cutting-edge fields such as brain-computer interfaces and rehabilitation robots, focusing on the maturity of technology and commercial viability [1] Group 1: Strategic Focus - The company is advancing clinical explorations and collaborations based on the maturity of technology and business synergy, given the high technical barriers and strict regulatory requirements in the medical industry [1] - The company aims to continuously communicate its strategic path focused on the entire industry chain of tumor pre-diagnosis and treatment through regular reports, announcements, and investor engagement activities [1] Group 2: Future Plans - The company plans to leverage resources from the Haier ecosystem to steadily enhance its core capabilities while actively seeking frontier collaboration opportunities that align with its strategy [1] - Management will continue to optimize team structure and broadly recruit professional talent to drive high-quality development of the company [1]

证券日报网讯盈康生命（300143）9月23日在互动平台回答投资者提问时表示，公司高度重视内部治理 与合规经营，通过持续加强制度建设，构建完善的廉洁从业制度体系，有效监督并防范贪污腐败、不正 当竞争等不道德的商业行为。公司严格执行《盈康生命商业行为准则》《盈康生命供应商行为准则》， 明确商业行为规范，为公司及合作伙伴划定清晰的道德底线，同时加强对内部员工的廉洁宣导与管理， 设立相应的监督与审计机制，确保商业活动的公正性和透明度。 ...

Group 1 - The core point of the article is that Yingkang Life (300143) reported a total of 20,500 shareholders as of September 19, 2025 [1]

盈康生命9月23日披露，截至9月20日公司股东户数为20500户，较上期（9月10日）减少3987户，环比降 幅为16.28%。 公司发布的半年报数据显示，上半年公司共实现营业收入8.43亿元，同比增长2.40%，实现净利润 6182.72万元，同比增长12.82%，基本每股收益为0.0832元，加权平均净资产收益率2.51%。 机构评级来看，近一个月该股获3家机构买入评级。预计目标价最高的是华泰证券，8月26日华泰证券发 布的研报给予公司目标价12.42元。（数据宝） （文章来源：证券时报网） 证券时报·数据宝统计，截至发稿，盈康生命最新股价为11.06元，下跌4.66%，本期筹码集中以来股价 累计下跌14.99%。具体到各交易日，2次上涨，7次下跌。 融资融券数据显示，该股最新（9月22日）两融余额为2.89亿元，其中，融资余额为2.89亿元，本期筹码 集中以来融资余额合计增加1133.88万元，增幅为4.09%。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 ...

Company Overview - Yingkang Life Technology Co., Ltd. is located in Qingdao, Shandong Province, and was established on August 6, 1998, with its listing date on December 9, 2010 [1] - The company primarily operates in the medical device and medical services sectors, focusing on the research, production, and sales of advanced medical equipment such as the Maxip radiation therapy equipment and Gamma Knife [1] - The revenue composition of the company is 77.47% from medical services, with 22.53% from equipment and consumables, and another 22.53% from medical devices [1] Stock Performance - On September 23, Yingkang Life's stock fell by 5%, trading at 11.02 CNY per share, with a total transaction volume of 92.35 million CNY and a turnover rate of 1.27%, resulting in a total market capitalization of 8.259 billion CNY [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Galaxy Fund has a significant position in Yingkang Life [2] - The Galaxy Kangle Stock A fund (519673) increased its holdings by 184,000 shares in the second quarter, bringing its total to 930,900 shares, which accounts for 5.06% of the fund's net value, making it the sixth-largest holding [2] - The fund has experienced a floating loss of approximately 539,900 CNY as of the latest report [2] Fund Manager Information - The fund manager of Galaxy Kangle Stock A is Fang Wei, who has been in the position for 4 years and 138 days [3] - The total asset size of the fund is 671 million CNY, with the best and worst fund returns during the manager's tenure being -4.55% and -18.43%, respectively [3]